A Japanese health ministry proposal to impose steeper price cuts on certain medicines deemed to carry poor cost-effectiveness profiles cleared…
HOME > REGULATORY
REGULATORY
- LDP Group to Make New Rules on Online OTC Drug Sales in the Diet Session, Consider Lawmaker-Sponsored Bill
January 22, 2013
- PAFSC’s 2nd Committee to Discuss GSK’s CLL Treatment Arzerra on January 31
January 21, 2013
- MHLW Mulling Measure to Encourage Welfare Recipients to Use Generics
January 21, 2013
- How Will Party’s Return Affect Healthcare and Drug Policy? LDP Back in Power for First Time in 3 Years
January 17, 2013
- MHLW to Launch Panel by Jan.-End to Discuss New Rule for Online OTC Drug Sales after Top Court Ruling
January 16, 2013
- MHLW to Make HPV, Hib, and Pneumococcal Vaccines Mandatory, Excluding Them from the FY2012 Extra Budget
January 16, 2013
- At Request of JMA, Pharmacists to Be Required to Confirm that Buyers of Switch OTC Version of Epadel Had Medical Exam Before Purchase
January 15, 2013
- Supreme Court OKs Online Sales of OTC Drugs, Rejects Govt Appeal
January 15, 2013
- MHLW Calls for Preventive Measures against Accidental Ingestion of Pharmaceutical Products by Children
January 15, 2013
- Focus May Be on Whether New Price Cutting Rule for Long-Listed Drugs Should Apply Only to Those Granted Premium
January 15, 2013
- MHLW Revises GCP Ordinance, Pushes Clinical Trials with Simple Contract Procedures
January 11, 2013
- PMDA Probes How Insurance Pharmacies Utilize Drug Safety Information
January 11, 2013
- MHLW’s Revised Budget Request for FY2013 under LDP for Innovation-Related Spending 40% Less than under DPJ
January 11, 2013
- MHLW Approves 2 Switch OTC Versions of Epadel
January 7, 2013
- MHLW Survey Finds Nearly 10% of Doctors Who Prescribe Prazaxa Are Unaware of Warnings in Blue Letter
December 28, 2012
- MHLW Compiling Database of Drug Approvals Overseas
December 28, 2012
- PMDA Review Period Reduced for Both Priority, Standard Products
December 28, 2012
- 2nd Abe Cabinet Inaugurated; Industry Awaits Decision on Perpetuation of Premium for New Drug Development
December 27, 2012
- MHLW Approves 23 Products Including Toviaz
December 26, 2012
- LDP to Finalize Tax Reform Outline for FY2013 by Late January
December 26, 2012
ページ
A Japanese drug pricing panel on November 11 discussed ways to respond to the US most-favored-nation (MFN) policy, with healthcare…
On paper, things should be looking up for Japan’s pharmaceutical wholesalers. Industry expectations are mounting that the average gap between NHI and market prices will narrow further in FY2026 from the previous year’s record low of 4.8%.A shrinking gap should…
Japan is set to add 16 new drugs to its NHI reimbursement price list on November 13, including a subcutaneous…
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…